Myelofibrosis is a serious bone marrow disorder that disrupts your body's normal production of blood cells. The result is extensive scarring in your bone marrow, leading to severe anemia, weakness, fatigue, and often, an enlarged spleen and liver. Myelofibrosis is an uncommon type of chronic leukemia — a cancer that affects the blood-forming tissues in the body. Myelofibrosis belongs to a group of diseases called myeloproliferative disorders.
Data of the Belgian survey indicated that 77% of the MF patients have a palpable spleen. In 41.9%, spleen size was ≥10 cm under the costal margin. In the Comfort II trial, 47% of the patients in the best available therapy (BAT)-arm received hydroxyurea and none reached a >35% spleen volume reduction, the endpoint of the trial.18 However, in a retrospective analysis of 40 MF patients treated with hydroxyurea, a clinical improvement was seen in 40% of the patients, including a reduction in palpable spleen length of ≥50% in 30%.
In the past, the treatment of myelofibrosis has depended on the symptoms and degree of the low blood counts. A long-term remission is possible for some patients with bone marrow transplantation. Such treatment should be considered for younger patients and some others. Other treatment may involve:Blood transfusions and medicines to correct anemia, Radiation and chemotherapy, Medicines to target a genetic mutation, Splenectomy if swelling causes symptoms, or to help with anemia.